CO7101247A2 - Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas - Google Patents
Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altasInfo
- Publication number
- CO7101247A2 CO7101247A2 CO14228077A CO14228077A CO7101247A2 CO 7101247 A2 CO7101247 A2 CO 7101247A2 CO 14228077 A CO14228077 A CO 14228077A CO 14228077 A CO14228077 A CO 14228077A CO 7101247 A2 CO7101247 A2 CO 7101247A2
- Authority
- CO
- Colombia
- Prior art keywords
- poly
- treatment
- upper respiratory
- polyinosinic
- formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 title abstract 2
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 title 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 2
- 201000009240 nasopharyngitis Diseases 0.000 abstract 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166595 | 2012-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7101247A2 true CO7101247A2 (es) | 2014-10-31 |
Family
ID=48430695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14228077A CO7101247A2 (es) | 2012-05-03 | 2014-10-15 | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9682096B2 (OSRAM) |
| EP (1) | EP2846767B1 (OSRAM) |
| JP (1) | JP6349304B2 (OSRAM) |
| KR (1) | KR102240042B1 (OSRAM) |
| CN (1) | CN104394846B (OSRAM) |
| AU (1) | AU2013255885C1 (OSRAM) |
| BR (1) | BR112014026957A8 (OSRAM) |
| CA (1) | CA2866230C (OSRAM) |
| CL (1) | CL2014002929A1 (OSRAM) |
| CO (1) | CO7101247A2 (OSRAM) |
| ES (1) | ES2911116T3 (OSRAM) |
| IN (1) | IN2014MN02359A (OSRAM) |
| MX (1) | MX2014013256A (OSRAM) |
| NZ (1) | NZ630040A (OSRAM) |
| RU (1) | RU2650636C2 (OSRAM) |
| SG (2) | SG11201406208QA (OSRAM) |
| WO (1) | WO2013164380A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6349304B2 (ja) | 2012-05-03 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 |
| CA2929142A1 (en) * | 2013-11-06 | 2015-05-14 | Janssen Sciences Ireland Uc | Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| KR20180004233A (ko) * | 2015-05-11 | 2018-01-10 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 |
| ES2715251B1 (es) | 2015-11-17 | 2020-09-07 | Bioncotech Therapeutics S L | Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina |
| AU2016365219A1 (en) * | 2015-11-30 | 2018-07-05 | Novus Therapeutics, Inc. | Compositions and methods for otologic prophylaxis and treatment |
| US20200060972A1 (en) | 2016-11-16 | 2020-02-27 | Janssen Sciences Ireland Unlimited Company | Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections |
| US10849921B2 (en) | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| US12226477B2 (en) * | 2018-06-29 | 2025-02-18 | Beijing Yisheng Biotechnology Co., Ltd. | Methods for preparing complex for enhancing immune response |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| CA2079509C (en) | 1991-10-01 | 2002-05-14 | Shigeyuki Takada | Prolonged release microparticle preparation and production of the same |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| CA2203843C (en) | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| CA2424892A1 (en) * | 2000-10-06 | 2002-04-11 | Jagotec Ag | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| US20040248837A1 (en) * | 2002-11-01 | 2004-12-09 | Eyal Raz | Methods of treating pulmonary fibrotic disorders |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| CN1867355A (zh) | 2003-08-11 | 2006-11-22 | 财团法人阪大微生物病研究会 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
| AU2004314706A1 (en) * | 2003-12-11 | 2005-08-11 | University Of Miami | Immunotherapy compositions, method of making and method of use thereof |
| CN101229378A (zh) | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
| ATE539767T1 (de) | 2005-06-08 | 2012-01-15 | Yisheng Biopharma Singapore Pte Ltd | Adjuvans auf basis von polyinosinsäure/polycytidylsäure |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| EP2046740B1 (en) | 2006-07-22 | 2012-05-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
| CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
| JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
| UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
| EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
| CN102281870B (zh) * | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| CN101491503A (zh) | 2008-12-17 | 2009-07-29 | 天津瑞普生物技术股份有限公司 | 一种用于宠物的聚肌胞滴丸及其制备方法 |
| SI3098239T1 (sl) | 2008-12-22 | 2020-03-31 | Targimmune Therapeutics Ag | Egfr-homing vektor dvoverižne rna za sistemsko zdravljenje raka |
| CN101757018A (zh) * | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
| AU2010232180B2 (en) | 2009-03-31 | 2016-09-22 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
| EP2598145A1 (en) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| JP6349304B2 (ja) | 2012-05-03 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 上気道感染症の処置のためのポリイノシン−ポリシチジル酸（ポリ（ｉ：ｃ））製剤 |
| CA2929142A1 (en) | 2013-11-06 | 2015-05-14 | Janssen Sciences Ireland Uc | Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
-
2013
- 2013-05-02 JP JP2015509432A patent/JP6349304B2/ja not_active Expired - Fee Related
- 2013-05-02 KR KR1020147028656A patent/KR102240042B1/ko not_active Expired - Fee Related
- 2013-05-02 CA CA2866230A patent/CA2866230C/en active Active
- 2013-05-02 SG SG11201406208QA patent/SG11201406208QA/en unknown
- 2013-05-02 EP EP13722334.3A patent/EP2846767B1/en active Active
- 2013-05-02 CN CN201380023084.4A patent/CN104394846B/zh not_active Expired - Fee Related
- 2013-05-02 AU AU2013255885A patent/AU2013255885C1/en not_active Ceased
- 2013-05-02 RU RU2014148544A patent/RU2650636C2/ru active
- 2013-05-02 MX MX2014013256A patent/MX2014013256A/es unknown
- 2013-05-02 SG SG10201607288VA patent/SG10201607288VA/en unknown
- 2013-05-02 WO PCT/EP2013/059079 patent/WO2013164380A1/en not_active Ceased
- 2013-05-02 IN IN2359MUN2014 patent/IN2014MN02359A/en unknown
- 2013-05-02 NZ NZ630040A patent/NZ630040A/en not_active IP Right Cessation
- 2013-05-02 US US14/398,573 patent/US9682096B2/en not_active Expired - Fee Related
- 2013-05-02 ES ES13722334T patent/ES2911116T3/es active Active
- 2013-05-02 BR BR112014026957A patent/BR112014026957A8/pt not_active Application Discontinuation
-
2014
- 2014-10-15 CO CO14228077A patent/CO7101247A2/es unknown
- 2014-10-29 CL CL2014002929A patent/CL2014002929A1/es unknown
-
2016
- 2016-06-13 US US15/180,603 patent/US9987300B2/en active Active
-
2018
- 2018-05-07 US US15/972,840 patent/US10485816B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2866230C (en) | 2020-08-18 |
| US20180325939A1 (en) | 2018-11-15 |
| AU2013255885A1 (en) | 2014-09-25 |
| AU2013255885C1 (en) | 2018-04-26 |
| MX2014013256A (es) | 2015-01-16 |
| KR20150008855A (ko) | 2015-01-23 |
| JP6349304B2 (ja) | 2018-06-27 |
| CN104394846A (zh) | 2015-03-04 |
| CN104394846B (zh) | 2018-10-19 |
| JP2015515968A (ja) | 2015-06-04 |
| NZ630040A (en) | 2016-10-28 |
| WO2013164380A1 (en) | 2013-11-07 |
| US20150140042A1 (en) | 2015-05-21 |
| SG11201406208QA (en) | 2014-11-27 |
| BR112014026957A2 (pt) | 2017-06-27 |
| US9682096B2 (en) | 2017-06-20 |
| KR102240042B1 (ko) | 2021-04-14 |
| CL2014002929A1 (es) | 2015-01-16 |
| US9987300B2 (en) | 2018-06-05 |
| EP2846767B1 (en) | 2022-01-26 |
| SG10201607288VA (en) | 2016-10-28 |
| EP2846767A1 (en) | 2015-03-18 |
| US20160296551A1 (en) | 2016-10-13 |
| RU2014148544A (ru) | 2016-06-27 |
| RU2650636C2 (ru) | 2018-04-16 |
| HK1203390A1 (en) | 2015-10-30 |
| BR112014026957A8 (pt) | 2018-01-16 |
| US10485816B2 (en) | 2019-11-26 |
| IN2014MN02359A (OSRAM) | 2015-08-14 |
| ES2911116T3 (es) | 2022-05-17 |
| AU2013255885B2 (en) | 2017-10-05 |
| CA2866230A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
| CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| MX2016005883A (es) | Formulaciones de acido poliinosinico-policitidilico (poli (i:c))para el tratamiento de infecciones del tracto respiratorio superior. | |
| MX377510B (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| TR201004464A2 (tr) | Kemik erimesi için formülasyon. | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
| BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento | |
| GB201204632D0 (en) | Delivery system | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| EA201890789A1 (ru) | Содержащая цинеол композиция для лечения заболеваний носа | |
| BR112015023872A2 (pt) | composição compreendendo arabinogalactano e poliofenóis de árvores de lariço |